Would a starting salary of over $160,000
turn you off? Well, maybe if you had a scientific PhD and had to wait four
months before the employer could decide whether to hire you or not, you would find
a spot elsewhere.
This is the situation the Food and Drug
Administration finds itself in, according to the Washington Post:
The Food and Drug
Administration has more than 700 job vacancies in its division that approves
new drugs, and top officials say the agency is struggling to hire and retain
staff because pharmaceutical companies lure them away.
“They can pay them
roughly twice as much as we can,” Janet Woodcock, who directs the FDA’s Center
for Drug Evaluation and Research (CDER), said at a rare-diseases summit
recently in Arlington, Va.
(Sidney Lupkin
& Sarah Jane Tribble, “Despite
ramped-up hiring, FDA continues to grapple with hundreds of vacancies,” Washington Post, November 1, 2016.)
As I’ve discussed before, the FDA is not short of money. On the
contrary, its budget for drug approvals has increased significantly over the
years. However, one reason it cannot hire enough staff to review applications
is that it is too slow to process hiring.
If it cannot
hire regulatory staff efficiently, how will it ever process drug approvals
efficiently?
The fundamental
problem is that the FDA is a monopoly, protected by government. Its staff do
not suffer if new medicines and devices are not approved in a timely manner.
Rather, patients, investors, and innovators suffer. The FDA has lots of reason
to complain, because that is how it increases its budget.
However, it has
no incentive to become more productive or efficient in approving new therapies.
A bigger budget just makes the FDA bigger, but not better. Patients need more
freedom to use new therapies without having their access strangled by the FDA.